Monoclonal antibody-based therapy strategies: providing options for the cancer patient.

@article{Milenic2002MonoclonalAT,
  title={Monoclonal antibody-based therapy strategies: providing options for the cancer patient.},
  author={Diane E. Milenic},
  journal={Current pharmaceutical design},
  year={2002},
  volume={8 19},
  pages={
          1749-64
        }
}
Treatment of patients with unconjugated MAb such as rituximab (Rituxan) the anti-CD20 MAb or trastuzumab (Herceptin) the anti-Her2 MAb, have shown efficacy in clinical trials and have gained approval from the Food and Drug Administration (FDA) has a result. Likewise, an anti-CD33 MAb conjugated with the antibiotic calicheamicin (Mylotarg) has proven… CONTINUE READING